

# Resource Summary Report

Generated by [FDI Lab - SciCrunch.org](https://fdi-lab.sci-crunch.org) on Apr 15, 2025

## AsPC-1

RRID:CVCL\_0152

Type: Cell Line

---

### Proper Citation

(RRID:CVCL\_0152)

---

### Cell Line Information

**URL:** [https://web.expasy.org/cellosaurus/CVCL\\_0152](https://web.expasy.org/cellosaurus/CVCL_0152)

**Proper Citation:** (RRID:CVCL\_0152)

**Sex:** Female

**Defining Citation:** [PMID:1630814](#), [PMID:1764370](#), [PMID:4023565](#), [PMID:6582512](#), [PMID:7182348](#), [PMID:7972006](#), [PMID:8026879](#), [PMID:8194712](#), [PMID:8286197](#), [PMID:9331070](#), [PMID:9665481](#), [PMID:10027410](#), [PMID:10408907](#), [PMID:11115575](#), [PMID:11169959](#), [PMID:11787853](#), [PMID:12692724](#), [PMID:14695172](#), [PMID:15126341](#), [PMID:15367885](#), [PMID:15688027](#), [PMID:15770730](#), [PMID:16912165](#), [PMID:18298655](#), [PMID:18380791](#), [PMID:20037478](#), [PMID:20164919](#), [PMID:20215515](#), [PMID:20418756](#), [PMID:21607521](#), [PMID:22460905](#), [PMID:22585861](#), [PMID:25167228](#), [PMID:25485619](#), [PMID:25877200](#), [PMID:25984343](#), [PMID:26216984](#), [PMID:26586397](#), [PMID:26589293](#), [PMID:27259358](#), [PMID:27397505](#), [PMID:27910856](#), [PMID:28196595](#), [PMID:29444439](#), [PMID:30894373](#), [PMID:30971826](#), [PMID:31068700](#), [PMID:31978347](#), [PMID:32782605](#), [PMID:35839778](#)

**Comments:** Caution: TP53 mutation indicated incorrectly as being at c.818G>A in PubMed=1630814., Omics: Transcriptome analysis by serial analysis of gene expression (SAGE)., Omics: Transcriptome analysis by RNAseq., Omics: Transcriptome analysis by microarray., Omics: SNP array analysis., Omics: shRNA library screening., Omics: Proteome analysis by 2D-DE/MS., Omics: Protein expression by reverse-phase protein arrays., Omics: miRNA expression profiling., Omics: Metabolome analysis., Omics: DNA methylation analysis., Omics: Deep quantitative proteome analysis., Omics: Deep proteome analysis., Omics: Deep exome analysis., Omics: CRISPR phenotypic screen., Omics: Array-based CGH., Population: Caucasian., Part of: NCI RAS program mutant KRAS cell line panel., Part of: MD Anderson Cell Lines Project., Part of: KuDOS 95 cell line panel., Part of: COSMIC cell lines project., Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line

Encyclopedia - CCLE).

**Category:** Cancer cell line

**Name:** AsPC-1

**Synonyms:** AsPc-1, Aspc-1, ASPC-1, As-PC1, ASPC1, AsPC1, Aspc1, AsPc1

**Cross References:** BTO:BTO\_0001864, CLO:CLO\_0001756, EFO:EFO\_0002112, MCCL:MCC:0000044, CLDB:cl289, AddexBio:C0018023/5061, ArrayExpress:E-MTAB-38, ArrayExpress:E-MTAB-783, ArrayExpress:E-MTAB-2706, ArrayExpress:E-MTAB-2770, ArrayExpress:E-MTAB-3610, ATCC:CRL-1682, BCRC:60494, BioGRID\_ORCS\_Cell\_line:259, BioSample:SAMN03471961, BioSample:SAMN10988235, cancercellines:CVCL\_0152, CCRID:1101HUM-PUMC000214, CCRID:3101HUMTCHu8, Cell\_Model\_Passport:SIDM00899, CGH-DB:160-1, CGH-DB:9271-4, ChEMBL-Cells:ChEMBL3307994, ChEMBL-Targets:ChEMBL612588, CLS:300158, Cosmic:707247, Cosmic:710851, Cosmic:724645, Cosmic:808166, Cosmic:868239, Cosmic:872994, Cosmic:910702, Cosmic:913308, Cosmic:918050, Cosmic:922255, Cosmic:923164, Cosmic:932514, Cosmic:933515, Cosmic:947398, Cosmic:948371, Cosmic:948740, Cosmic:949230, Cosmic:1006364, Cosmic:1090374, Cosmic:1108341, Cosmic:1198210, Cosmic:1320465, Cosmic:1366285, Cosmic:1477433, Cosmic:1571783, Cosmic:1644318, Cosmic:1995341, Cosmic:2434085, Cosmic:2668289, Cosmic-CLP:910702, DepMap:ACH-000222, ECACC:96020930, EGA:EGAS00001000610, EGA:EGAS00001000978, GDSC:910702, GEO:GSM206446, GEO:GSM383935, GEO:GSM495808, GEO:GSM621911, GEO:GSM784702, GEO:GSM886870, GEO:GSM887935, GEO:GSM1024396, GEO:GSM1177959, GEO:GSM1177960, GEO:GSM1177961, GEO:GSM1374394, GEO:GSM1374395, GEO:GSM1374396, GEO:GSM1588607, GEO:GSM1588619, GEO:GSM1669603, GEO:GSM1906985, GEO:GSM1906986, GEO:GSM1906987, IARC\_TP53:311, IARC\_TP53:21127, IBRC:C10154, IGRhCellID:AsPC1, IZSLER:BS TCL 171, KCLB:21682, LiGeA:CCLE\_008, LINCS\_LDP:LCL-1730, NCBI\_Iran:C558, PharmacDB:AsPC1\_67\_2019, PRIDE:PXD003198, PRIDE:PXD030304, PRIDE:PXD032263, Progenetix:CVCL\_0152, PubChem\_Cell\_line:CVCL\_0152, SKY/M-FISH/CGH:1997, Wikidata:Q54750736

**ID:** CVCL\_0152

**Record Creation Time:** 20250131T193935+0000

**Record Last Update:** 20250131T194152+0000

---

## Ratings and Alerts

No rating or validation information has been found for AsPC-1.

No alerts have been found for AsPC-1.

---

## Data and Source Information

Source: [Cellosaurus](#)

---

## Usage and Citation Metrics

We found 784 mentions in open access literature.

**Listed below are recent publications.** The full list is available at [FDI Lab - SciCrunch.org](#).

Zhou Y, et al. (2024) Nudt21-mediated alternative polyadenylation of MZT1 3'UTR contributes to pancreatic cancer progression. *iScience*, 27(2), 108822.

Ohara Y, et al. (2024) ELAPOR1 induces the classical/progenitor subtype and contributes to reduced disease aggressiveness through metabolic reprogramming in pancreatic cancer. *International journal of cancer*, 155(3), 569.

He C, et al. (2024) Vitamin B6 Competition in the Tumor Microenvironment Hampers Antitumor Functions of NK Cells. *Cancer discovery*, 14(1), 176.

Wehrli M, et al. (2024) Mesothelin CAR T Cells Secreting Anti-FAP/Anti-CD3 Molecules Efficiently Target Pancreatic Adenocarcinoma and its Stroma. *Clinical cancer research : an official journal of the American Association for Cancer Research*, 30(9), 1859.

Shrestha H, et al. (2024) The Janus kinase 1 is critical for pancreatic cancer initiation and progression. *Cell reports*, 43(5), 114202.

Ohara Y, et al. (2024) LMO3 is a suppressor of the basal-like/squamous subtype and reduces disease aggressiveness of pancreatic cancer through glycerol 3-phosphate metabolism. *Carcinogenesis*.

Moreno P, et al. (2024) ADRA2A promotes the classical/progenitor subtype and reduces disease aggressiveness of pancreatic cancer. *bioRxiv : the preprint server for biology*.

Liu M, et al. (2024) The crosstalk between macrophages and cancer cells potentiates pancreatic cancer cachexia. *Cancer cell*, 42(5), 885.

Zheng JH, et al. (2024) A CLIC1 network coordinates matrix stiffness and the Warburg effect to promote tumor growth in pancreatic cancer. *Cell reports*, 43(8), 114633.

Zhang S, et al. (2024) Roflumilast inhibits tumor growth and migration in STK11/LKB1 deficient pancreatic cancer. *Cell death discovery*, 10(1), 124.

Yang Y, et al. (2024) WW domains form a folded type of nuclear localization signal to guide YAP1 nuclear import. *The Journal of cell biology*, 223(6).

Long AW, et al. (2024) Heterodimerization of T cell engaging bispecific antibodies to enhance specificity against pancreatic ductal adenocarcinoma. *Journal of hematology & oncology*, 17(1), 20.

Yoshikawa T, et al. (2024) Development of a chimeric cytokine receptor that captures IL-6 and enhances the antitumor response of CAR-T cells. *Cell reports. Medicine*, 5(5), 101526.

Bootsma S, et al. (2024) Exploiting a subtype-specific mitochondrial vulnerability for successful treatment of colorectal peritoneal metastases. *Cell reports. Medicine*, 5(5), 101523.

Nguyen CDK, et al. (2024) PRMT1 promotes epigenetic reprogramming associated with acquired chemoresistance in pancreatic cancer. *Cell reports*, 43(5), 114176.

Zhou Y, et al. (2024) The YY1-CPT1C signaling axis modulates the proliferation and metabolism of pancreatic tumor cells under hypoxia. *Biochemical pharmacology*, 227, 116422.

Wang K, et al. (2024) Multi-Algorithm Analysis Reveals Pyroptosis-Linked Genes as Pancreatic Cancer Biomarkers. *Cancers*, 16(2).

Schäfer TE, et al. (2024) Biomarker screen for efficacy of oncolytic virotherapy in patient-derived pancreatic cancer cultures. *EBioMedicine*, 105, 105219.

Tao J, et al. (2024) CALB2 drives pancreatic cancer metastasis through inflammatory reprogramming of the tumor microenvironment. *Journal of experimental & clinical cancer research : CR*, 43(1), 277.

Tapia Contreras C, et al. (2024) KRASG 12C-inhibitor-based combination therapies for pancreatic cancer: insights from drug screening. *Molecular oncology*.